NEUROPACE INC (NPCE) Stock Price, Quote, News and Overview
NASDAQ:NPCE - Nasdaq - US6412881053 - Common Stock - Currency: USD
NPCE Quote, Performance and Key Statistics
13.22
+0.11 (+0.84%)
The current stock price of NPCE is 13.22 USD. In the past month the price increased by 12.13%. In the past year, price increased by 91.32%.
NPCE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.95 | 232.41B | ||
| ISRG | INTUITIVE SURGICAL INC | 72.3 | 197.97B | ||
| BSX | BOSTON SCIENTIFIC CORP | 38.99 | 155.73B | ||
| SYK | STRYKER CORP | 30.54 | 146.23B | ||
| MDT | MEDTRONIC PLC | 15.09 | 106.43B | ||
| BDX | BECTON DICKINSON AND CO | 12.25 | 49.47B | ||
| EW | EDWARDS LIFESCIENCES CORP | 30.08 | 45.88B | ||
| IDXX | IDEXX LABORATORIES INC | 45.03 | 41.60B | ||
| RMD | RESMED INC | 26.96 | 35.89B | ||
| DXCM | DEXCOM INC | 52 | 33.64B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.33 | 32.30B | ||
| STE | STERIS PLC | 26.25 | 24.09B |
Related stock screener links
About NPCE
Company Profile
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 184 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.
Company Info
NEUROPACE INC
455 N. Bernardo Avenue
Mountain View CALIFORNIA US
CEO: Michael Favet
Employees: 184
Phone: 16502372700
NEUROPACE INC / NPCE FAQ
What is the stock price of NEUROPACE INC today?
The current stock price of NPCE is 13.22 USD. The price increased by 0.84% in the last trading session.
What is the ticker symbol for NEUROPACE INC stock?
The exchange symbol of NEUROPACE INC is NPCE and it is listed on the Nasdaq exchange.
On which exchange is NPCE stock listed?
NPCE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEUROPACE INC stock?
13 analysts have analysed NPCE and the average price target is 17.19 USD. This implies a price increase of 30.06% is expected in the next year compared to the current price of 13.22. Check the NEUROPACE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEUROPACE INC worth?
NEUROPACE INC (NPCE) has a market capitalization of 433.62M USD. This makes NPCE a Small Cap stock.
How many employees does NEUROPACE INC have?
NEUROPACE INC (NPCE) currently has 184 employees.
What are the support and resistance levels for NEUROPACE INC (NPCE) stock?
NEUROPACE INC (NPCE) has a support level at 12.45 and a resistance level at 13.23. Check the full technical report for a detailed analysis of NPCE support and resistance levels.
Is NEUROPACE INC (NPCE) expected to grow?
The Revenue of NEUROPACE INC (NPCE) is expected to grow by 18.85% in the next year. Check the estimates tab for more information on the NPCE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEUROPACE INC (NPCE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NPCE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NPCE, evaluating the profitability, health, valuation and growth aspects
- NEUROPACE INC (NPCE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEUROPACE INC (NPCE) Sales and EPS estimates to see what analysts future expectations are.
- NEUROPACE INC (NPCE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEUROPACE INC (NPCE) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEUROPACE INC (NPCE) Stock Chart to make your own analysis
- NEUROPACE INC (NPCE) Latest news and press-releases to stay up to date.
Does NEUROPACE INC (NPCE) stock pay dividends?
NPCE does not pay a dividend.
When does NEUROPACE INC (NPCE) report earnings?
NEUROPACE INC (NPCE) will report earnings on 2025-08-11, after the market close.
What is the Price/Earnings (PE) ratio of NEUROPACE INC (NPCE)?
NEUROPACE INC (NPCE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
What is the Short Interest ratio of NEUROPACE INC (NPCE) stock?
The outstanding short interest for NEUROPACE INC (NPCE) is 1.66% of its float. Check the ownership tab for more information on the NPCE short interest.
NPCE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to NPCE. When comparing the yearly performance of all stocks, NPCE is one of the better performing stocks in the market, outperforming 95.02% of all stocks.
NPCE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NPCE. NPCE may be in some trouble as it scores bad on both profitability and health.
NPCE Financial Highlights
Over the last trailing twelve months NPCE reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 29.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.51% | ||
| ROE | -102.21% | ||
| Debt/Equity | 2.46 |
NPCE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to NPCE. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 15.64% and a revenue growth 18.85% for NPCE